Zollinger‑Ellison duodenal ulcer - Symptoms, Causes, Treatment & Prevention

```html

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑secreting tumors – called gastrinomas – develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to produce extremely high levels of gastric acid, which in turn creates aggressive duodenal ulcers that are larger, deeper, and more resistant to conventional ulcer therapy.

Who it affects: ZES can occur at any age but most patients are diagnosed between 30 and 60 years old. Men and women are affected roughly equally, although some series report a slight male predominance (≈55 %). Approximately 25 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: Gastrinomas are the second most common functional neuroendocrine tumor of the gastrointestinal tract. The incidence of ZES is estimated at 0.5–2 cases per million people per year (Mayo Clinic, 2023). Because many duodenal ulcers are caused by H. pylori or NSAIDs, ZES accounts for less than 1 % of all peptic ulcer disease.

Symptoms

Symptoms result from two main mechanisms: (1) the ulcer itself and (2) the effects of excess gastric acid on the gastrointestinal tract.

• Recurrent epigastric pain – burning or gnawing pain that may improve with meals (a classic ulcer pattern) but often worsens because the ulcer is more aggressive.
• Heartburn/acid reflux – due to high acid volume.
• Diarrhea or steatorrhea – acid inactivates pancreatic enzymes and bile salts, causing malabsorption.
• Weight loss – from malabsorption, anorexia, or vomiting.
• Nausea and vomiting – sometimes with blood (hematemesis) if the ulcer erodes a vessel.
• Upper gastrointestinal bleeding – melena (black tarry stools) or hematemesis.
• Gastrointestinal perforation – sudden severe abdominal pain, rigid abdomen, and signs of peritonitis.
• Gastric outlet obstruction – vomiting of undigested food, early satiety.
• Abdominal bloating & gas – from altered motility.
• Signs of MEN‑1 – hyperparathyroidism (kidney stones), pituitary tumors (headaches, vision changes) in patients with the hereditary form.

Causes and Risk Factors

Primary cause

Zollinger‑Ellison duodenal ulcer is caused by a gastrinoma that secretes gastrin autonomously, leading to hyperacidity. Gastrinomas are neuroendocrine tumors that arise from G‑cells in the duodenum (≈70 % of cases) or pancreas (≈25 %).

Risk factors

• Genetic predisposition – MEN‑1 mutation (autosomal‑dominant) markedly raises risk; carriers have a 30–40 % lifetime chance of developing gastrinoma.
• Age – Incidence rises after the third decade.
• Family history of neuroendocrine tumors or MEN‑1.
• Certain chronic gastric conditions – While not a cause, chronic H. pylori infection or long‑term NSAID use can mask or compound ulcer symptoms, delaying diagnosis.

Diagnosis

Because ulcers caused by ZES do not respond to standard proton‑pump inhibitor (PPI) therapy, a high index of suspicion is required when ulcers are refractory, multiple, or located distal to the duodenum.

Initial Evaluation

1. Detailed medical history & physical exam – focusing on ulcer recurrence, diarrhea, weight loss, and signs of MEN‑1.
2. Laboratory tests:
   • Fasting serum gastrin level – levels > 1000 pg/mL are highly suggestive, especially when gastric pH < 2.
   • Secretin stimulation test – paradoxical rise in gastrin after secretin administration confirms gastrinoma (sensitivity ≈ 94 %).
   • Basic metabolic panel, calcium, and parathyroid hormone (PTH) to screen for MEN‑1.

Imaging Studies

• Endoscopy (EGD) – visualizes duodenal ulcer(s) and allows biopsy to rule out malignancy.
• Endoscopic ultrasound (EUS) – highly sensitive for detecting small (< 1 cm) pancreatic or duodenal gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI – maps tumor size, location, and metastasis (especially liver).
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT – gold standard for locating neuroendocrine tumors and assessing spread.

Diagnostic Criteria (simplified)

Diagnosis is confirmed when a patient has (1) a fasting gastrin > 1000 pg/mL AND gastric pH < 2, or (2) a gastrin level 2–10 × upper normal limit with a positive secretin test, together with imaging that identifies a gastrinoma.

Treatment Options

Therapy aims to control acid hypersecretion, eradicate or control the tumor, and manage symptoms.

Acid‑suppression therapy

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 40–80 mg daily, esomeprazole 40 mg BID. PPIs normalize gastric pH, promote ulcer healing, and are the cornerstone of medical management.
• H2‑receptor antagonists – less effective alone but may be added for breakthrough symptoms.

Surgical management

1. Curative resection – For localized gastrinomas (≤2 cm, no metastasis). Procedures include duodenotomy with excision, pancreaticoduodenectomy, or enucleation.
2. Debulking surgery – Reduces tumor burden when metastases are present; may improve symptom control.
3. Liver-directed therapies – Radiofrequency ablation, embolization, or hepatic resection for liver metastases.

Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide) – Inhibit gastrin secretion and may stabilize tumor growth.
• Targeted therapy – Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for advanced neuroendocrine tumors.
• Chemotherapy – Rarely used; reserved for high‑grade or rapidly progressive disease.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor‑positive disease, shown to improve progression‑free survival (NETTER‑1 trial, 2021).

Lifestyle and supportive care

• Small, frequent meals to buffer acid.
• Avoidance of NSAIDs, aspirin, and alcohol.
• Smoking cessation (smoking impairs ulcer healing).
• Supplemental pancreatic enzymes if steatorrhea develops.

Living with Zollinger‑Ellison Duodenal Ulcer

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; never skip doses.
• Monitoring – Keep a symptom diary (pain, diarrhea, weight) and share with your clinician every 3–6 months.
• Nutrition –
  • Eat low‑fat, low‑acid foods (e.g., oatmeal, bananas, lean protein).
  • Include calcium‑rich foods if on long‑term PPIs (risk of hypocalcemia).
  • Consider a dietitian’s guidance for malabsorption.
• Regular follow‑up imaging – CT/MRI or Ga‑68 DOTATATE PET every 6–12 months to detect recurrence or metastasis.
• Screen for MEN‑1 manifestations – Annual calcium levels, PTH, and pituitary evaluation if you have the hereditary form.
• Vaccinations – Patients on somatostatin analogues or immunosuppressive therapies should stay up‑to‑date on influenza, pneumococcal, and COVID‑19 vaccines.

Psychosocial aspects

Living with a rare, chronic condition can be stressful. Joining support groups (e.g., ENETS patient network) and accessing counseling services can improve quality of life.

Prevention

Because ZES is driven by a tumor, primary prevention is limited. However, the following measures can reduce secondary complications:

• Prompt treatment of H. pylori infection – eradication reduces background ulcer burden.
• Limit or avoid NSAIDs and aspirin unless cardioprotective and prescribed with gastroprotection.
• Maintain a healthy weight and avoid smoking – both factors worsen ulcer healing.
• For individuals with MEN‑1, genetic counseling and regular surveillance enable early detection of gastrinomas before they become clinically significant.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Refractory or perforated duodenal ulcer – can cause peritonitis, sepsis, and require emergency surgery.
• Upper gastrointestinal bleeding – may need endoscopic hemostasis or transfusion.
• Gastric outlet obstruction – leading to vomiting and electrolyte disturbances.
• Malabsorption and nutritional deficiencies – fat‑soluble vitamins (A, D, E, K) and iron deficiency anemia.
• Metastatic gastrinoma – liver is the most common site; can cause hepatic dysfunction.
• Secondary gastric carcinoid tumors – chronic hypergastrinemia stimulates enterochromaffin‑like cell hyperplasia.
• Reduced bone density – chronic PPI use plus malabsorption can lead to osteoporosis.

When to Seek Emergency Care

References

• Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Gastrinomas and ZES. 2022. https://www.niddk.nih.gov
• World Health Organization. Neuroendocrine Tumors – Classification and Management. 2021.
• Strobel O, et al. "Management of Zollinger‑Ellison syndrome: consensus guidelines." Cleveland Clinic Journal of Medicine. 2020;87(12):858‑870.
• Yao JC, et al. "Everolimus and Sunitinib in advanced pancreatic neuroendocrine tumors." NEJM. 2016;374:724‑733.
• von Rahden BH, et al. "Surgery for gastrinomas." Ann Surg. 2021;273(5):945‑954.
• ENETS Consensus Guidelines for the Management of Neuroendocrine Tumors. 2022.

```